| 23rd week of 2012 patent applcation highlights part 41 |
| Patent application number | Title | Published |
|---|
| 20120141402 | NANOSCOPIC HAIR CARE PRODUCTS - The present invention is directed to a hair treatment preparation comprising a payload in an intimate relationship to a polymeric nanostructure, the polymeric nanostructure being reactive to hair or capable of being immobilized onto or in hair. The nanoscopic nature of the entities being engineered ensures three distinct characteristics. First, the imparted attribute can be either nearly permanent or semi-permanent, depending on the attachment chemistry. In the semi-permanent version, the intended effect can be controllably erased by removal of the nanostructure by simple chemical or physical means. Second, the nanoscopic entities are invisibly small. Their presence does not deteriorate the hand or feel of the hair. Third, the nano-technology approach is infinitely flexible and adaptable. It can be coupled with many existing dyes, colorants, UV absorbers, fragrances, softening agents and the like for hair treatment. Methods for treating hair with the hair treatment preparations of the invention are also encompassed. | 2012-06-07 |
| 20120141403 | AQUEOUS FATTY MONOAMINE-CONTAINING CARRIER SYSTEMS FOR WATER-INSOLUBLE MATERIALS - The present invention is drawn to a carrier composition containing: (a) at least one fatty monoamine compound; (b) at least one nonionic surfactant; (c) at least one anionic silicone; and (d) at least one water-insoluble material, and wherein the composition, when combined with an aqueous phase, forms an aqueous delivery system which is both stable, and clear to slightly hazy/limpid in appearance. | 2012-06-07 |
| 20120141404 | AQUEOUS FATTY QUATERNARY AMINE-CONTAINING CARRIER SYSTEMS FOR WATER-INSOLUBLE MATERIALS - The present invention is drawn to a carrier composition containing: (a) at least one fatty quaternary amine compound; (b) at least one nonionic surfactant; (c) at least one anionic silicone; and (d) at least one water-insoluble material, and wherein the composition, when combined with an aqueous phase, forms an aqueous delivery system which is both stable, and clear to slightly hazy/limpid in appearance. | 2012-06-07 |
| 20120141405 | AQUEOUS POLYAMINE-CONTAINING CARRIER SYSTEMS FOR WATER-INSOLUBLE MATERIALS - The present invention is drawn to a carrier composition containing: (a) at least one polyamine compound comprising at least two amino groups; (b) at least one nonionic surfactant; (c) at least one anionic silicone; and (d) at least one water-insoluble material, and wherein the composition, when combined with an aqueous phase, forms an aqueous delivery system which is both stable, and clear to slightly hazy/limpid in appearance. | 2012-06-07 |
| 20120141406 | AGENT FOR KERATINOUS FIBERS, COMPRISING AT LEAST ONE ACRYLATE/GLYCERYL ACRYLATE COPOLYMER, AT LEAST ONE FILM-FORMING AND/OR SOLIDIFYING POLYMER AND AT LEAST ONE ESTER OIL - The present invention is an agent for treating keratinous fibers, particularly human hair, comprising: (a) at least one glyceryl acrylates/acrylates copolymer; (b) at least one film-forming and/or setting polymer; and (c) at least one ester oil. The agent may additionally comprise a polyol such as glycerin. The agent is best suited for temporarily deforming hairs into a desired shape or style and for the general caring of hair. | 2012-06-07 |
| 20120141407 | CHEMICAL OPTIMIZATION DURING WASTEWATER TREATMENT, ODOR CONTROL AND USES THEREOF - Compositions for the use of sewage or wastewater treatment, controlling odors or a combination thereof are disclosed, wherein the composition comprises at least one iron-based compound. Furthermore, methods of reducing the odors in a sewage or wastewater system are disclosed that include: adding a composition comprising at least one iron-based compound to a sewage or wastewater system. As used herein, the phrase “at least one iron-based compound” includes ferrous chloride, ferric chloride, ferrous sulfate, ferrate, polyferric sulfate, Ferix-3 (Fe | 2012-06-07 |
| 20120141408 | High Water Content Ophthalmic Devices - An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and further wherein the ophthalmic device has an evaporative dehydration barrier layer on the surface thereof. A method for the mitigation of evaporative corneal dehydration employing the high water content ophthalmic device is also disclosed. | 2012-06-07 |
| 20120141409 | MULTI-VALENT ADJUVANT DISPLAY - The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group. | 2012-06-07 |
| 20120141410 | METHOD AND COMPOSITION FOR THE TREATMENT OF MODERATE TO SEVERE KERATOCONJUNCTIVITIS SICCA - Embodiments of the invention relate to compositions and methods of dry eye or keratoconjunctivitis sicca. | 2012-06-07 |
| 20120141411 | Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response - Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described. | 2012-06-07 |
| 20120141412 | METHODS OF TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH COMPOSITIONS COMPRISING EXTRACTS OF ASTRAGALUS MEMBRANACEUS - The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of | 2012-06-07 |
| 20120141413 | USE OF IL-15 PREPARATIONS TO TREAT LYMPHOPENIA - The present invention provides method for promoting the maturation and export of T cells from thymic tissue by contacting the thymic tissue with supraphysiological levels of interleukin (IL)-15. The present invention also provides methods for preventing, alleviating, reducing, and/or inhibiting lymphopenia or peripheral depletion of lymphocytes in a patient in need thereof by administering to the patient IL-15. | 2012-06-07 |
| 20120141414 | Bimacrocylic HCV NS3 Protease Inhibitors - Inhibitors of the hepatitis C virus (HCV) NS3 protease are provided. In particular, bimacrocyclic compounds and their pharmaceutical compositions for the treatment of HCV infections are provided. Methods of making the bimacrocyclic compounds and their pharmaceutical compositions, and methods of using the compounds for treating HCV infections are also provided. | 2012-06-07 |
| 20120141415 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2012-06-07 |
| 20120141416 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF - The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases. | 2012-06-07 |
| 20120141417 | Collagen Preparation and Method of Isolation - Collagen compositions, methods for preparing those collagen compositions, and graft compositions formed from those collagen compositions are provided. In particular, methods of isolating collagen that exhibits an enhanced rate of polymerization and enhanced microstructural and mechanical properties upon polymerization, such collagen compositions, and graft compositions formed from such collagen compositions are provided. | 2012-06-07 |
| 20120141418 | Treatment of Melanoma Using HSV Mutant - Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (R | 2012-06-07 |
| 20120141419 | Biodegradable Linkers for Molecular Therapies - A method and a composition for delivery of a biomaterial to an animal cell or a tissue, the composition includes (a) a biomaterial; (b) a biodegradable cross-linker portion having a hydrolyzable bond, wherein the biodegradable cross-linker portion is covalently bound to the biomaterial; and (c) a substrate, wherein the substrate is covalently bound to the biodegradable cross-linker portion, provided that the biodegradable cross-linker is adapted to hydrolyze by breaking the hydrolyzable bond and thereby release and deliver the biomaterial. A process of making the composition is also provided. | 2012-06-07 |
| 20120141420 | TARGETED DELIVERY OF G-CSF FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to a method of treating Amyotrophic Lateral Sclerosis by the targeted delivery of granulocyte-colony stimulating factor to the central nervous system with an adeno-associated virus (AAV) vector. | 2012-06-07 |
| 20120141421 | LIQUID VIRAL FORMULATIONS - Provided herein are liquid viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The liquid viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients and a liquid carrier. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage. | 2012-06-07 |
| 20120141422 | WIDESPREAD GENE DELIVERY TO THE RETINA USING SYSTEMIC ADMINISTRATION OF AAV VECTORS - The present invention relates to compositions and methods, in particular to methods based on systemic administration of scAAV, for delivering genes to cells of the retina of mammals, and in particular to photoreceptor cells, ganglion cells, glial cells, inner nuclear layer cells or cells of the retinal pigmented epithelium. | 2012-06-07 |
| 20120141423 | NOVEL PAENIBACILLUS POLYMYXA STRAIN, ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE - The present invention relates to a novel | 2012-06-07 |
| 20120141424 | Materials and Methods for the Treatment of Hypertension - The present invention is directed to materials and methods for the treatment of hypertension and ischemia comprising administering at least one therapeutic agent selected from the group consisting of vascular endothelial growth factor-C product and vascular endothelial growth factor-D product, and optionally, when treating hypertension, a standard of care anti-hypertensive agent. | 2012-06-07 |
| 20120141425 | VIRUS-LIKE PARTICLE VECTOR FOR DELIVERY OF PHARMACEUTICAL AGENTS, A PROCESS FOR THE MANUFACTURE THEREOF, ITS USES AND A PHARMACEUTICAL COMPOSITION - The embodiment of the invention is a virus-like particle vector, a process for the manufacture thereof, use of the virus-like particle vector and a pharmaceutical composition, which contains the virus-like particle vector. The vector is intended for the delivery of therapeutic agents into specific mammalian tissues, especially low molecular weight agents, in particular low molecular weight anti-cancer drugs into cancer tissues. More specifically, the invention relates to the virus-like particle vector, which constitutes an adenoviral dodecahedron with the therapeutic substance encapsulated or covalently linked. | 2012-06-07 |
| 20120141426 | Reovirus for the Treatment of Cellular Proliferative Disorders - Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated. | 2012-06-07 |
| 20120141427 | Attenuated Strain of Myxoma Virus for Use as an Oncolytic Drug - The invention relates to the use of an attenuated vaccinal strain of | 2012-06-07 |
| 20120141428 | MUSCLE-DERIVED CELLS (MDCS) FOR TREATING MUSCLE- OR BONE-RELATED INJURY OR DYSFUNCTION - The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-1, transforming growth factor-a, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins. | 2012-06-07 |
| 20120141429 | Method for stimulating osteogenesis - Nanostructures such as nanowires, nanosprings, nanorods, and nanoparticles, when maintained in contact with a source of bone cells, enhance the proliferation of the bone cells and integration bone into the nanostructures. The nanostructures may or may not be coated with a metal or metal oxide coating and preferably are textured. Such coated or non-coated nanostructures may be utilized on the surface of bone implants to enhance osseointegration of the implants. | 2012-06-07 |
| 20120141430 | Tissue Regeneration Membrane - The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention. | 2012-06-07 |
| 20120141431 | METHODS FOR IDENTIFYING, ISOLATING, AND UTILIZING ENDOCRINE PROGENITOR CELLS FROM ADULT HUMAN PANCREAS - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin- | 2012-06-07 |
| 20120141432 | USE OF CATALYTIC ANTIOXIDANT TO PRESERVE STEM CELL PHENOTYPE AND CONTROL CELL DIFFERENTIATION - Methods are disclosed herein for maintaining stem cells in an undifferentiated state in vitro. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant. Also disclosed are methods for the increasing the number of stem cells in vitro while maintaining the stem cells in an undifferentiated state. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant and an effective amount of one or more growth factors that promotes the expansion of the stem cells. | 2012-06-07 |
| 20120141433 | Vaporized Stem Cell Derivatives for Topical and Other Therapeutic Uses - The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and/or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications. | 2012-06-07 |
| 20120141434 | Methods for Selecting Expanded Stem Cell Populations - A method and criteria are provided for selecting expanded hematopoietic stem cell populations for allogenic transplantation, the selected cell populations having high probability of engraftment and positive clinical outcome. | 2012-06-07 |
| 20120141435 | USE OF OLIVE LEAF EXTRACTS IN A PHARMACEUTICAL COMPOSITION FOR INDUCING ANGIOGENESIS AND VASCULOGENESIS - The invention relates to the use of olive leaf extracts for producing a pharmaceutical composition capable of inducing angiogenesis and vascularization. In general, the composition can be used for therapeutic applications in order to promote the differentiation of stem cells into endothelial progenitor cells (EPCs) and/or mature endothelial cells, as well as to induce the vessel formation from said endothelial cells. The vascularization-inducing angiogenic composition of the invention is intended for, inter alia, cardiovascular disease, ischemic processes in general, ulcers, and wound healing in both human and veterinary medicine. | 2012-06-07 |
| 20120141436 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY - Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject. | 2012-06-07 |
| 20120141437 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2012-06-07 |
| 20120141438 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2012-06-07 |
| 20120141439 | BIOARTIFICAL LUNG - Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. | 2012-06-07 |
| 20120141440 | FOAMYVIRUS VECTORS AND METHODS OF USE - The disclosure of the present application provides foamyvirus vectors, as well as methods and kits involving the same. In at least one embodiment, a plurality of recombinant vectors comprises an expression sequence encoding at least one component of a foamyvirus particle, wherein at least one codon of the expression sequence is optimized for expression in | 2012-06-07 |
| 20120141441 | Methods and Compositions for Treatment of Muscular Dystrophy - The present disclosure provides methods for introducing a gene encoding a muscle membrane protein into a cell isolated from a subject to generate a genetically modified cell. The genetically modified cell may be introduced back, e.g., engrafted into the subject. The isolated cell may be additionally modified by introducing into the isolated cell a gene encoding one or more reprogramming transcription factors that induce the cell to form an induced pluripotent stem cell. The genetically modified cell may be differentiated in vitro to form muscle cell precursors before engrafting into the subject. Also provided are compositions comprising autologous cells isolated from a subject which cells comprise a muscle membrane protein gene integrated into a genome attachment site in the genome of the cell. The autologous cell may be an induced pluripotent cell or a mesenchymal stem cell, such as an adipose-derived mesenchymal stem cell (AD-MSC). | 2012-06-07 |
| 20120141442 | MEANS AND METHODS FOR COUNTERACTING, DELAYING AND/OR PREVENTING ADVERSE ENERGY METABOLISM SWITCHES IN HEART DISEASE - The invention relates to the fields of molecular biology and medicine, more specifically to treatment and prevention of heart disease. The invention provides alternative methods for counteracting, diminishing, treating, delaying and/or preventing heart disease. | 2012-06-07 |
| 20120141443 | SHORT-TIME HIGH TEMPERATURE TREATMENT GENERATES MICROBIAL PREPARATIONS WITH ANTI-INFLAMMATORY PROFILES - The present invention generally relates to the field of bacteria. In particular, the present invention concerns “short time high temperature” treated probiotics and/or dairy starter cultures and applications of these bacteria. One embodiment of the present invention relates to “short-time high temperature” treated probiotics and/or dairy starter cultures and their use to prepare compositions to treat or prevent inflammatory disorders. | 2012-06-07 |
| 20120141444 | NUTRITIONALLY BALANCED STANDARD TUBE FEEDING FORMULA CONTAINING PROBIOTICS - The present invention relates to the field of enteral nutrition to be administered via tube feeding. In particular, the present invention provides tube feeding formulas for complete nutrition comprising probiotic micro-organisms. Such probiotic micro-organisms may be non-replicating micro-organisms, such as bioactive heat-treated probiotic micro-organisms, for example. | 2012-06-07 |
| 20120141445 | NUTRITION FOR IMPROVING MUSCLE STRENGTH IN ELDERLY - The invention pertains to a composition for stimulating muscle strength in elderly, comprising whey protein, free BCAA and probiotic bacteria, wherein the composition comprises one or more free BCAAs selected from the group consisting of leucine, isoleucine and valine, and at least 50 g whey protein per 100 g dry weight of the total composition. Also, the invention pertains to a composition additionally comprising one or more dietary fibers selected from the group of pectins, pectates, alginates, fructans, fructooligosaccharides, indigestible dextrins, galactooligosaccharides, xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligosaccharides and fucooligosaccharides, and to the use of such composition in dietary management of malnutrition of elderly. | 2012-06-07 |
| 20120141446 | Oral Nutritional Supplement Delivery System - A composition for increasing the bioavailability of nutrients in humans and animals comprising an oil base emulsion into which nutrients selected from the group comprising omega fatty acids, vitamin D, Co Q10, green tea extract, and policosanol are added. | 2012-06-07 |
| 20120141447 | NUTRITIONAL SUPPLEMENT - A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol. | 2012-06-07 |
| 20120141448 | Method for increasing muscle mass and strength - Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones. | 2012-06-07 |
| 20120141449 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2012-06-07 |
| 20120141450 | RISK MARKERS FOR CARDIOVASCULAR DISEASE - The invention relates to a method for determining the risk of suffering a cardiovascular disease based on the presence of different polymorphisms as well as to kits for practicing the above method. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented means for carrying out said method. | 2012-06-07 |
| 20120141451 | FIBROBLAST GROWTH FACTOR RECEPTOR-DERIVED PEPTIDES BINDING TO NCAM - The present invention relates to the use of peptides that are capable of binding to, and modulating the activity of NCAM. The peptides are peptide fragments of FGFRs. They are derived from two distinct binding sites for binding of the immunoglobulin-like module 2 of FGFR to NCAM F3 modules 1-2. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein NCAM and/or FGFRs play a prominent role. | 2012-06-07 |
| 20120141452 | Targeted Therapeutic Proteins - Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided. | 2012-06-07 |
| 20120141453 | Glycosidase Enzymes - A thermostable glycosidase enzymes derived from various | 2012-06-07 |
| 20120141454 | Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases - The present methods and compositions are of use for treatment of conditions involving fibrosis, such as Peyronie's disease plaque, penile corporal fibrosis, penile veno-occlusive dysfunction, Dupuytren's disease nodules, vaginal fibrosis, clitoral fibrosis, female sexual arousal disorder, abnormal wound healing, keloid formation, general fibrosis of the kidney, bladder, prostate, skin, liver, lung, heart, intestines or any other localized or generalized fibrotic condition, vascular fibrosis, arterial intima hyperplasia, atherosclerosis, arteriosclerosis, restenosis, cardiac hypertrophy, hypertension or any condition characterized by excessive fibroblast or smooth muscle cell proliferation or deposition of collagen and extracellular matrix in the blood vessels and/or heart. In certain embodiments, the compositions may comprise a PDE-4 inhibitor, a PDE-5 inhibitor, a compound that elevates cGMP and/or PKG, a stimulator of guanylyl cyclase and/or PKG, a combination of a compound that elevates cGMP, PKG or NO with an antioxidant that decreases ROS, or a compound that increases MMP activity. | 2012-06-07 |
| 20120141455 | INSOLUBLE DIETARY FIBER-CONTAINING MATERIALS DERIVED FROM CEREAL SEEDS - This invention provides a product safe for treating, improving or preventing an inflammatory bowel disease such as ulcerative colitis, and provides a product comprising an insoluble dietary fiber obtained by enzymatic treatment of seeds of a grain plant(s) or germinated young seeds thereof, as well as a food or drink or medicament comprising the product. | 2012-06-07 |
| 20120141456 | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System - The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist. | 2012-06-07 |
| 20120141457 | Lateral Flow Immunoassay for Complement Activation and Methods of Use for Point-of-Care Assessment of Complement-Associated Disorders - A method for treating an individual at risk for a complement-associated disorder is provided, including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d). Lateral flow immunoassays and a method of monitoring an individual suffering from a complement-associated disorder are also provided herein. | 2012-06-07 |
| 20120141458 | COMPOSITIONS AND METHODS FOR TREATMENT IN BROAD-SPECTRUM, UNDIFFERENTIATED OR MIXED CLINICAL APPLICATIONS - The disclosure provides improved compositions and methods for passive immunization. In embodiments, a composition comprising a synergistic combination of specific polyclonal antibodies in a carrier matrix is provided. The disclosure provides effective, economical compositions and methods for the treatment of diarrhea and enteric infections in broad-spectrum, undifferentiated, or mixed clinical applications. | 2012-06-07 |
| 20120141459 | MOLECULAR TARGETS FOR ALS AND RELATED DISORDERS - Provided herein are compositions and methods for diagnosis, risk assessment, research, and therapy related to amyotrophic lateral sclerosis (ALS) and ALS-related disorders. In particular, the present invention relates to mutations in the UBQLN2 gene that cause dominantly inherited chromosome X-linked ALS and ALS/dementia. | 2012-06-07 |
| 20120141460 | METHOD FOR THE PRODUCTION OF VARIABLE DOMAINS - The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties. | 2012-06-07 |
| 20120141461 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING FIBROTIC DISORDERS - The present invention relates to biomarkers, therapeutic targets, and therapeutic agents for treating and diagnosing firotic disorders. In particular, the present invention relates to diagnosis, drug screening, and therapeutic targeting of NOX4 biomarkers of pulmonary fibrosis and other fibrotic diseases and conditions. | 2012-06-07 |
| 20120141462 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF B CELL CHRONIC LYMPHOCYTIC LEUKEMIA - This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such. | 2012-06-07 |
| 20120141463 | Method Of Identifying Membrane Ig Specific Antibodies And Use Thereof For Targeting Immunoglobulin-Producing Precursor Cells - The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. | 2012-06-07 |
| 20120141464 | BINDING MEMBER FOR GM-CSF RECEPTOR - Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFRα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid leukaemia and atherosclerosis is also provided. | 2012-06-07 |
| 20120141465 | VIRUS VACCINATION AND TREATMENT METHODS WITH OX40 AGONIST COMPOSITIONS - The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization. | 2012-06-07 |
| 20120141466 | COMPOSITION AND METHOD FOR TREATMENT OF REPERFUSION INJURY AND TISSUE DAMAGE - The present invention provides compounds and methods for the treatment and prophylaxis of ischemia reperfusion injury. In particular the invention provides compounds which function to suppress Toll-like Receptor 2 biological function or expression. | 2012-06-07 |
| 20120141467 | Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma - Provided herein is a method for treating a tracheo-bronchial-alveolar tract disease in a subject in need thereof, the method comprising the step of administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof. Also provided is a method for treating non-Hodgkin's lymphoma in a subject in need thereof, the method comprising the step of administering to the subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of ascorbate or a derivative thereof. | 2012-06-07 |
| 20120141468 | MAINTENANCE OF PLATELET INHIBITION DURING ANTIPLATELET THERAPY - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2012-06-07 |
| 20120141469 | CRIPTO ANTAGONISM OF ACTIVIN AND TGF-B SIGNALING - Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b. | 2012-06-07 |
| 20120141470 | T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF - The invention relates to compositions which bind T cell inhibitory receptor molecules and modulate T cell activity, and methods of using such compositions. Such compositions include biliary glycoprotein binding agents. Methods for modulating killer T cell activities, including cytotoxicity and proliferation also are provided. | 2012-06-07 |
| 20120141471 | Methods of Inhibiting Metastasis from Cancer - The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX | 2012-06-07 |
| 20120141472 | METHODS OF SCORING GENE COPY NUMBER IN A BIOLOGICAL SAMPLE USING IN SITU HYBRIDIZATION - Disclosed herein are methods of predicting prognosis of a neoplastic disease (such as lung cancer, for example NSCLC), including determining the IGF1R gene copy number in a biological sample from a patient having a neoplastic disease; wherein an increase in IGF1R copy number predicts a good prognosis of the neoplastic disease in the patient. Also disclosed herein are methods of scoring copy number of a gene of interest in a biological sample. The method includes identifying individual cells in the sample having highest number of signals for the gene of interest detected by in situ hybridization, counting the number of signals for the gene of interest in the identified individual cells and determining an average number of signals per cell. | 2012-06-07 |
| 20120141473 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS - Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis. | 2012-06-07 |
| 20120141474 | TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease - Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation. | 2012-06-07 |
| 20120141475 | TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease - Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation. | 2012-06-07 |
| 20120141476 | FcGammaRIIB Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that bind FcγRIIB with greater affinity than said antibodies or fragments binds FcγRIIA. The invention encompasses the use of such antibodies or fragments for the treatment of diseases related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune diseases, inflammatory diseases or IgE-mediated allergic disorders. The present invention also encompasses the use of such antibodies and fragments in combination with other cancer therapies, methods of enhancing the therapeutic effect of therapeutic antibodies, and methods of enhancing efficacy of vaccine compositions. | 2012-06-07 |
| 20120141477 | Antibodies That Specifically Bind to ABeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 2012-06-07 |
| 20120141478 | COMPOSITIONS AND METHODS FOR DELIVERING ANTI-ACTIVATED RAS ANTIBODIES - The present invention concerns a chimeric polypeptide comprising: (i) a first domain comprising an amino-acid sequence facilitating active transport across a biological membrane by the binding to an glycosaminoglycan, which is selected from the group consisting of a) (XBBBXXBX)n; (XBBXBX)n; c) (BBXmBBXp)n; d) (XBEXXTBX)n; e) (BXmBB)n; f) (BmXX)n or g) an antibody fragment, wherein each B is independently a basic amino acid preferably lysine or arginine; each X is independently a non-basic amino acid preferably hydrophobic amino acid; each m is independently an integer from zero to five; each n is independently an integer between one and ten; and each p is independently an integer between zero to five; and (ii) a second domain comprises an anti-activated RAS neutralizing antibody, fragment or derivative thereof; a polynucleotide encoding said polypeptide; a pharmaceutical composition comprising said polynucleotide or said polypeptide; and the use of said polypeptide for the manufacture of a medicament for treating cancer. | 2012-06-07 |
| 20120141479 | Histone Deacetylase Inhibitors Sensitize Cancer Cells To Epidermal Growth Factor Inhibitors - Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity. | 2012-06-07 |
| 20120141480 | METHODS OF TREATING WITH ANTI-FACTOR D ANTIBODIES - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2012-06-07 |
| 20120141481 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 2012-06-07 |
| 20120141482 | MOLECULAR COMPLEXES WHICH MODIFY IMMUNE RESPONSES - Extracellular domains of transmembrane heterodimeric proteins, particularly T cell receptor and major histocompatibility complex proteins, can be covalently linked to the heavy and light chains of immunoglobulin molecules to provide soluble multivalent molecular complexes with high affinity for their cognate ligands. The molecular complexes can be used, inter alia, to detect and regulate antigen-specific T cells and as therapeutic agents for treating disorders involving immune system regulation, such as allergies, autoimmune diseases, tumors, infections, and transplant rejection. | 2012-06-07 |
| 20120141483 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES - The present invention provides indane acetic acids and their derivatives and methods for the treatment and/or prevention of psoriasis and/or Alzheimer's diseases using the same. | 2012-06-07 |
| 20120141484 | METHODS OF PREVENTING INFLAMMATION AND TREATING PAIN USING ANTI-NGF COMPOSITIONS - Monovalent agents, including Fab fragments and monovalent monoclonal antibodies analogous to MetMab, having binding specificity to human Nerve Growth Factor (“NGF”), and methods treating pain in an individual wherein there is no substantial increase in the inflammatory response of the individual following administration of the monovalent agents. | 2012-06-07 |
| 20120141485 | METHODS OF PREVENTING OR TREATING PAIN USING ANTI-NGF ANTIBODIES - Antibodies and antibody fragments thereof with binding specificity to human Nerve Growth Factor (NGF) and methods of use for treating pain. Methods of treating pain or eliciting an analgesic effect comprising administering an effective amount of an anti-human NGF antibody or antibody fragment thereof, which inhibits the association of NGF with TrkA, and/or p75. These methods may optionally further comprising administering an effective amount of a second anti-human NGF antibody or fragment thereof (e.g., one which inhibits the association of NGF with p75, or one that inhibits the association of NGF with TrkA.) | 2012-06-07 |
| 20120141486 | HUMAN MONOCLONAL ANTIBODY - The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22. | 2012-06-07 |
| 20120141487 | MORAXELLA CATARRHALIS ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen from a | 2012-06-07 |
| 20120141488 | NOVEL G PROTEIN COUPLED RECEPTOR PROTEIN AND USE THEREOF - Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided. Further, a composition for the treatment and prevention of cancer, comprising an oligonucleotide inhibiting the expression of a gene encoding the GPCR polypeptide or an antibody against the GPCR protein, and a method for screening a modulator of the GPCR protein or a cancer therapeutic agent are provided. | 2012-06-07 |
| 20120141489 | Hypoxia Induced Mitogenic Factor - We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II. | 2012-06-07 |
| 20120141490 | Antibodies That Bind Selectively To P25 And Uses Therefor - The present invention relates to a monoclonal antibody or fragment thereof, which binds specifically to the cyclin-dependent kinase 5 (Cdk | 2012-06-07 |
| 20120141491 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS - The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases. | 2012-06-07 |
| 20120141492 | ANTI-IL 17A /IL-17F CROSS-REACTIVE ANTIBODIES AND METHODS OF USE THEREOF - This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2012-06-07 |
| 20120141493 | HUMAN BINDING MOLECULES HAVING KILLING ACTIVITY AGAINST STAPHYLOCOCCI AND USES THEREOF - Described are human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from | 2012-06-07 |
| 20120141494 | FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB - Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject. | 2012-06-07 |
| 20120141495 | METHOD FOR SUPPRESSING TUMOR GROWTH BY BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR, AND METHOD FOR DIAGNOSING MALIGNANT NEOPLASMS - The invention pertains to the field of medicine, particularly to methods for suppressing the growth of tumors, which comprise blocking the pathological pathway of human fibroblast growth factor/receptor 1 (domains II and IIIc), and for diagnosing malignant neoplasms leading to an excessive proliferation of tumor cells and to the formation of new vessels accompanied by the growth of primary tumors and metastases. This pathway also represents an independent mechanism of tumor resistance to preparations acting on other pathological pathways. Blocking the aforementioned pathway using various substances that neutralize the receptor by bonding only with domains II and IIIc thereof results in the interruption or slow-down of tumor growth. This receptor can also be used as a target for delivery of diagnostic agents being largely present in tumor cells. The invention enables developing new agents for diagnosing and treating diseases related to excessive proliferation and neovascularization. | 2012-06-07 |
| 20120141496 | IAP BIR DOMAIN BINDING COMPOUNDS - The present invention, according to several embodiments, comprises a compound represented by Formula I: | 2012-06-07 |
| 20120141497 | METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS - The present invention provides, among other things, methods of purifying or recovering proteins, in particular, small modular immunopharmaceutical (SMIPs™) proteins, from protein preparations containing high molecular weight (HMW) aggregates and other impurities based on hydroxyapatite chromatography. In some embodiments, the hydroxyapatite chromatography is used in combination with affinity chromatography and/or ion exchange chromatography. In some embodiments, inventive methods according to the invention involve no more than three chromatography steps. The present invention also provides proteins such as SMIPs™ purified according to the invention and pharmaceutical compositions containing the same. | 2012-06-07 |
| 20120141498 | USE OF PKC ISOZYMES FOR DIAGNOSIS AND TREATMENT OF NEUROBLASTOMA - The present invention pertains to the use of PKC-epsilon (PKC-ε), PKC-delta (PKC-δ), PKC-eta, and/or PKC-theta as biomarker(s) for prediction and/or detection of neuroblastoma, as well as therapeutic targets for treatment of neuroblastoma. | 2012-06-07 |
| 20120141499 | SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOIETIN-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 2012-06-07 |
| 20120141500 | Antibodies Against Human Angiopoietin 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2012-06-07 |
| 20120141501 | Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component - The present inventors identified inhibition of a combination of EGFR ligands that serve as targets for inhibition of cancer cell proliferation. More specifically, EREG antagonists and TGFα antagonists were found to be useful as inhibitors of cell growth. The present invention relates to pharmaceutical compositions containing EGF family ligand antagonists as components. | 2012-06-07 |
